Kratka digitalna izobraževanja o različnih vidikih obravnave srčnega popuščanja za vse zdravnike v sodelovanju z Mediately pripravljajo kolegi iz Programa za napredovalo srčno popuščanje in transplantacije srca.

V tretjem delu boste tudi s ponazoritvijo s primeri tipičnih bolnikov s srčnim popuščanjem izvedeli, kdaj, s čim in s kakšnimi odmerki zdraviti bolnika s srčnim popuščanjem.

<a href="https://public.mediately.co/assets/wp-uploads/2024/03/29134431/CME-SI-HFschool-Poglajen.pptx.pdf">Vsebino izobraževanja si lahko ogledate v predstavitvi.</a>

<a href="https://mediately.co/si/cme/CME-SI-HeartFailureSchool1/LandingPage">Povezava do 1. dela vsebine Digitalne šole srčnega popuščanja: Definicija in klasifikacije</a> <a href="https://mediately.co/si/cme/CME-SI-HeartFailureSchool2/LandingPage">Povezava do 2. dela vsebine Digitalne šole srčnega popuščanja: Diagnostika</a> <a href="https://mediately.co/si/cme/CME-SI-HeartFailureSchool4/LandingPage">Povezava do 4. dela vsebine Digitalne šole srčnega popuščanja</a>

<ol>
<li>McMurray, John J V et al. “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.” European heart journal vol. 33,14 (2012): 1787-1847.</li>
<li>Yancy, Clyde W et al. “2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.” Journal of the American College of Cardiology vol. 62,16 (2013): e147-239.</li>
<li>Oktay, A Afşin et al. “The emerging epidemic of heart failure with preserved ejection fraction.” Current heart failure reports vol. 10,4 (2013): 401-410.</li>
<li>Shah, Kevin S et al. “Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.” Journal of the American College of Cardiology vol. 70,20 (2017): 2476-2486.</li>
<li>Dickstein, Kenneth et al. “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).” European heart journal vol. 29,19 (2008): 2388-2442.</li>
<li>Ponikowski, Piotr et al. “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.” European heart journal vol. 37,27 (2016): 2129-2200.</li>
<li>McMurray, John JV, et al. &#8220;Angiotensin–neprilysin inhibition versus enalapril in heart failure.&#8221; New England Journal of Medicine 371.11 (2014): 993-1004.</li>
<li>McMurray, John JV, et al. &#8220;Dapagliflozin in patients with heart failure and reduced ejection fraction.&#8221; New England Journal of Medicine 381.21 (2019): 1995-2008.</li>
<li>Packer, Milton, et al. &#8220;Cardiovascular and renal outcomes with empagliflozin in heart failure.&#8221; New England Journal of Medicine 383.15 (2020): 1413-1424.</li>
<li>McDonagh, Theresa A et al. “2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.” European heart journal vol. 44,37 (2023): 3627-3639.</li>
<li>Solomon, Scott D., et al. &#8220;Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction.&#8221; New England Journal of Medicine 381.17 (2019): 1609-1620.</li>
<li>Solomon, Scott D., et al. &#8220;Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.&#8221; New England Journal of Medicine 387.12 (2022): 1089-1098.</li>
<li>Anker, Stefan D., et al. &#8220;Empagliflozin in heart failure with a preserved ejection fraction.&#8221; New England Journal of Medicine385.16 (2021): 1451-1461.</li>
<li>Butler, Javed et al. “Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.” European heart journal vol. 42,13 (2021): 1203-1212.</li>
</ol>

Avtor/ji

Opravite izobraževanje in pridobite kreditne točke

Reference

Uporabite Mediately aplikacijo

Uporabite Mediately aplikacijo